ATNM (STOCKS)
Actinium Pharmaceuticals, Inc
$1.000000
-0.010000 (-0.99%)
Prev close: $1.010000
Company Information
- Exchange
- XASE
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Sandesh Seth
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $31.53M
- Employees
- 31
- P/E (TTM)
- -1.34
- P/B (TTM)
- 13.75
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
6
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.18 | $-0.24 | +0.0597 | +24.91% |
|
Mar 2025 (Q4)
|
$-0.20 | $-0.19 | -0.0096 | -5.04% |
|
Sep 2025 (Q3)
|
$-0.16 | $-0.33 | +0.1698 | +51.49% |
|
Jun 2025 (Q2)
|
$-0.22 | $-0.36 | +0.1370 | +38.38% |
Financial Statements
| Revenues | $90.00K |
| Nonoperating Income/Loss | $2.04M |
| Operating Expenses | $25.60M |
| Research and Development | $17.63M |
| Other Operating Expenses | $7.98M |
| Operating Income/Loss | -$25.51M |
| Income/Loss From Continuing Operations After Tax | -$23.47M |
| Income/Loss From Continuing Operations Before Tax | -$12.31M |
| Net Income/Loss | -$23.47M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$23.47M |
| Net Income/Loss Available To Common Stockholders, Basic | -$23.47M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.75 |
| Diluted Earnings Per Share | -$0.75 |
| Basic Average Shares | 93,629,463 |
| Diluted Average Shares | 93,629,463 |
| Assets | $45.44M |
| Current Assets | $43.26M |
| Noncurrent Assets | $2.18M |
| Fixed Assets | $268.00K |
| Other Non-current Assets | $1.91M |
| Liabilities | $43.13M |
| Current Liabilities | $7.35M |
| Noncurrent Liabilities | $35.79M |
| Equity | $2.30M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $2.30M |
| Liabilities And Equity | $45.44M |
| Net Cash Flow From Operating Activities | -$22.88M |
| Net Cash Flow From Operating Activities, Continuing | -$22.88M |
| Net Cash Flow From Investing Activities | -$7.68M |
| Net Cash Flow From Investing Activities, Continuing | -$7.68M |
| Net Cash Flow From Financing Activities | -$218.00K |
| Net Cash Flow From Financing Activities, Continuing | -$218.00K |
| Net Cash Flow | -$30.76M |
| Net Cash Flow, Continuing | -$30.78M |
| Comprehensive Income/Loss | -$23.51M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$23.51M |
| Other Comprehensive Income/Loss | -$39.45M |